Stacy B Menees1,2, Amanda Guentner3, Samuel W Chey1, Richard Saad1, William D Chey1. 1. Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan, USA. 2. Division of Gastroenterology, Ann Arbor Veterans' Administration Hospital, Ann Arbor, Michigan, USA. 3. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
BACKGROUND: The aim of this study was to assess how US gastroenterologists perceive and utilize over-the-counter (OTC) and prescription medications for gastroesophageal reflux disease (GERD) and chronic constipation (CC). METHODS: A total of 3,600 randomly selected American Gastroenterological Association (AGA) members were mailed a 27-question survey that assessed their perceptions and use of OTC and prescription medications. The χ(2) test and Student's t-test were utilized for bivariate analysis. RESULTS: A total of 830 gastroenterologists (23.1%) completed the survey. For the typical acid reflux patient, 50% of gastroenterologists recommended OTC proton pump inhibitors (PPIs), 13% recommended an OTC histamine2 receptor antagonist, whereas 33% recommended a prescription PPI. However, in the typical CC patient, 97% of gastroenterologists initially utilized OTC treatments. The vast majority of gastroenterologists felt that OTC brand name and store brand PPIs (76%) and polyethylene glycol (PEG 3350; 90%) were equally effective. Despite this, a minority "always" or "very often" directed their patients to purchase a store brand PPI (35%) or laxative (40%). In addition, gastroenterologists tended to underestimate the cost savings associated with store brand medicines and had limited knowledge regarding the regulation of store brands. CONCLUSIONS: Among US gastroenterologists, OTC medications now dominate primary therapy of GERD and CC. Despite feeling that name brand and store brand PPIs and laxatives are equally effective, the majority of gastroenterologists recommend brand name medicines and underestimate the cost savings associated with store brands. In this age of accountable care, greater efforts to help physicians and patients to better utilize their health-care dollars is warranted.
BACKGROUND: The aim of this study was to assess how US gastroenterologists perceive and utilize over-the-counter (OTC) and prescription medications for gastroesophageal reflux disease (GERD) and chronic constipation (CC). METHODS: A total of 3,600 randomly selected American Gastroenterological Association (AGA) members were mailed a 27-question survey that assessed their perceptions and use of OTC and prescription medications. The χ(2) test and Student's t-test were utilized for bivariate analysis. RESULTS: A total of 830 gastroenterologists (23.1%) completed the survey. For the typical acid reflux patient, 50% of gastroenterologists recommended OTC proton pump inhibitors (PPIs), 13% recommended an OTC histamine2 receptor antagonist, whereas 33% recommended a prescription PPI. However, in the typical CC patient, 97% of gastroenterologists initially utilized OTC treatments. The vast majority of gastroenterologists felt that OTC brand name and store brand PPIs (76%) and polyethylene glycol (PEG 3350; 90%) were equally effective. Despite this, a minority "always" or "very often" directed their patients to purchase a store brand PPI (35%) or laxative (40%). In addition, gastroenterologists tended to underestimate the cost savings associated with store brand medicines and had limited knowledge regarding the regulation of store brands. CONCLUSIONS: Among US gastroenterologists, OTC medications now dominate primary therapy of GERD and CC. Despite feeling that name brand and store brand PPIs and laxatives are equally effective, the majority of gastroenterologists recommend brand name medicines and underestimate the cost savings associated with store brands. In this age of accountable care, greater efforts to help physicians and patients to better utilize their health-care dollars is warranted.
Authors: R A Faaij; J M Van Gerven; I Jolivet-Landreau; A A Masclee; E M Vendrig; R C Schoemaker; L D Jacobs; A F Cohen Journal: Aliment Pharmacol Ther Date: 1999-12 Impact factor: 8.171
Authors: Peter J Kahrilas; Nicholas J Shaheen; Michael F Vaezi; Stephen W Hiltz; Edgar Black; Irvin M Modlin; Steve P Johnson; John Allen; Joel V Brill Journal: Gastroenterology Date: 2008-10 Impact factor: 22.682
Authors: Nilay D Shah; Denesh K Chitkara; G Richard Locke; Patrick D Meek; Nicholas J Talley Journal: Am J Gastroenterol Date: 2008-06-28 Impact factor: 10.864
Authors: Meghan B Skiba; Lindsay N Kohler; Tracy E Crane; Elizabeth T Jacobs; Aladdin H Shadyab; Ikuko Kato; Linda Snetselaar; Lihong Qi; Cynthia A Thomson Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-27 Impact factor: 4.254
Authors: Brian E Lacy; Elizabeth P Shea; Machelle Manuel; Jessica L Abel; Hancheng Jiang; Douglas C A Taylor Journal: PLoS One Date: 2021-01-11 Impact factor: 3.240